American Society of Hematology

ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise.

Guidelines and Quality Care

Resources to help practicing hematologists improve the quality
of care provided to patients

Drug Resources

Newly approved therapies and access information on hematologic drugs

Consult a Colleague

Service that provides advice on clinical questions in one to two days

Professional Development

Services to support hematologists with continuing medical education and recertification

Clinical Priorities

Resources to help hematologists understand federal programs, policy developments, and relevant issues affecting clinical practice

ASH Practice Update

Email newsletter highlighting the Society's latest educational offerings and developments impacting clinicians

View all Ask the Hematologist
  • Safety Information on Varubi (Rolapitant) Injectable Emulsion

    The Oncology Center of Excellence of the U.S. Food and Drug Administration is informing health care providers about new safety information for Varubi® (rolapitant) injectable emulsion, a substance P/neurokinin (NK-1) receptor antagonist indicated for the prevention of delayed nausea and vomiting associated with cancer chemotherapy in adults.

  • FDA Approves Axicabtagene Ciloleucel for Large B-Cell Lymphoma

    On October 18, 2017, the U.S. Food and Drug Administration granted regular approval to axicabtagene ciloleucel (YESCARTA™, Kite Pharma, Inc.) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

  • FDA Simplifies IRB Requirements for Individual Patient Expanded Access

    On October 3, 2017, the U.S. Food and Drug Administration (FDA) announced updates to three final guidance documents, including Form FDA 3926 and its instructions, to simplify Institutional Review Board (IRB) review requirements for physicians seeking to treat an individual patient with an investigational drug under expanded access. The updates allow for a waiver of the requirement for review and approval at a convened IRB meeting if the physician instead obtains concurrence by the IRB chairperson (or a designated IRB member) before treatment use begins.

  • FDA Grants Accelerated Approval to Copanlisib for Relapsed Follicular Lymphoma

    On September 14, 2017, the U.S. Food and Drug Administration granted accelerated approval to copanlisib (ALIQOPA™, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.

View all FDA alerts
  • Update on Tax Reform

    On December 20, the House of Representatives and the Senate voted to approve H.R. 1, tax reform legislation. Select members of each chamber came together to resolve disagreements between the two versions passed by the House and Senate.

  • 2017 Action of the Affordable Care Act

    Congress spent much of 2017 focused on the repeal and replace of the Affordable Care Act (ACA). Included is a summary of Congress and the Administration’s actions on repeal and replace of the ACA that occurred in 2017.

  • 2017 ASH Advocacy Activities

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2017.

  • 2017 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2017.

View all policy news
back to top